Right- and left-sided colorectal cancers respond differently to cetuximab.
CONCLUSIONS: The addition of cetuximab to chemotherapy in both first- and second-line treatments of mCRC may only benefit patients with primary LSCRC.
PMID: 26111811 [PubMed - in process]
Source: Chinese Journal of Cancer - Category: Cancer & Oncology Tags: Chin J Cancer Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Erbitux | Students | Study | Universities & Medical Training